Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma
Yuwa Ando, Tomokazu Kawaoka, Kei Amioka, et al.
Oncology (2021) Vol. 99, Iss. 8, pp. 507-517
Closed Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 321-338
Open Access | Times Cited: 68
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, et al.
Liver Cancer (2023) Vol. 13, Iss. 1, pp. 99-112
Open Access | Times Cited: 45
External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Han Li, Zhenying Wu, Jiali Chen, et al.
Clinical and Experimental Medicine (2022) Vol. 23, Iss. 5, pp. 1537-1549
Open Access | Times Cited: 34
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
Hidekatsu Kuroda, Takayoshi Oikawa, Masashi Ninomiya, et al.
Liver Cancer (2022) Vol. 11, Iss. 4, pp. 383-396
Open Access | Times Cited: 33
Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma
Katsuki Miyazaki, Yuji Morine, Caiming Xu, et al.
Cells (2023) Vol. 12, Iss. 4, pp. 612-612
Open Access | Times Cited: 20
Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study
Dongdong Xia, Wei Bai, Enxin Wang, et al.
Liver Cancer (2022) Vol. 11, Iss. 4, pp. 368-382
Open Access | Times Cited: 28
Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World
Xiaowei Li, Zhigang Fu, Xiaoxia Chen, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 28
TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
Zhanwang Xiang, Guohong Li, Luwen Mu, et al.
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 14
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Yuhang Chen, Shengyuan Dai, Chien‐shan Cheng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 5
Recent therapeutics in hepatocellular carcinoma.
Zhe Fan, Pengcheng Zhou, Binghui Jin, et al.
PubMed (2023) Vol. 13, Iss. 1, pp. 261-275
Closed Access | Times Cited: 11
Impact of anatomical liver resection for hepatocellular carcinoma in preventing early‐phase local recurrence after surgery
Akira Shimizu, Kôji Kubota, Tsuyoshi Notake, et al.
Journal of Hepato-Biliary-Pancreatic Sciences (2024) Vol. 31, Iss. 8, pp. 513-527
Open Access | Times Cited: 4
Super-enhancers in hepatocellular carcinoma: regulatory mechanism and therapeutic targets
Xuejin Lu, Meizi Zhu, Xueliang Pei, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy
Junpeng Luo, Zhimei Huang, Murong Wang, et al.
BMC Gastroenterology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis
YiFeng Liang, L M Gan, DeJin Zeng, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 10, pp. 2652-2664
Closed Access | Times Cited: 3
Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
Liwei Sun, Xuelong Xu, Fanguang Meng, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 15
Predictive Factors of Complete Response to Transarterial Chemoembolization in Intermediate Stage Hepatocellular Carcinoma beyond Up-To-7 Criteria
Natsuhiko Saito, Hideyuki Nishiofuku, Takeshi Sato, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2609-2609
Open Access | Times Cited: 8
Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma
Yusuke Kawamura, Norio Akuta, Junichi Shindoh, et al.
Cancers (2023) Vol. 15, Iss. 15, pp. 3789-3789
Open Access | Times Cited: 8
Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
Masatoshi Kudo
Cancers (2021) Vol. 13, Iss. 21, pp. 5475-5475
Open Access | Times Cited: 20
Efficacy of Transarterial Chemoembolization Combined with Molecular Targeted Agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
Zhenzhen Zhang, Yanfang Wu, Tang‐Hui Zheng, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3710-3710
Open Access | Times Cited: 14
Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis
Dailong Li, Siqi Liu, Chunlai Cheng, et al.
Medicine (2023) Vol. 102, Iss. 35, pp. e34811-e34811
Open Access | Times Cited: 7
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects
Masatoshi Kudo
Liver Cancer (2022) Vol. 11, Iss. 6, pp. 487-496
Open Access | Times Cited: 9
Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies
Neil Mehta, Robin Katie Kelley, Francis Y. Yao
Hepatology (2023) Vol. 80, Iss. 1, pp. 238-253
Closed Access | Times Cited: 5
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma
Satoshi Kobayashi, Taito Fukushima, Makoto Ueno, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 8
Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis
Di Pan, Haonan Liu, Xiao Ma, et al.
Journal of Gastrointestinal and Liver Diseases (2023) Vol. 32, Iss. 2, pp. 222-229
Open Access | Times Cited: 4
Systemic Treatment in Intermediate Stage (Barcelona Clinic Liver Cancer-B) Hepatocellular Carcinoma
Dimitrios Karagiannakis
Cancers (2023) Vol. 16, Iss. 1, pp. 51-51
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top